[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Esperion Therapeutics CFO Benjamin Halladay reported a sale and recent employee-plan purchase on Form 4. On 09/17/2025 he disposed of 7,046 shares of Esperion common stock at a price of $2.808 per share to satisfy tax obligations tied to vested restricted stock units. Following the reported transactions, Mr. Halladay beneficially owns 474,862 shares, which the filing notes includes 7,446 shares recently acquired through Esperion's Employee Stock Purchase Plan. The filing was signed by power of attorney on 09/18/2025.

Insights

Financial Analyst

TL;DR: Insider sale to cover taxes plus ESPP purchase left the CFO with 474,862 shares; routine disclosure with limited market impact.

The Form 4 discloses a common pattern: an insider sold 7,046 shares at $2.808 to satisfy tax obligations from vested restricted stock units while also participating in the company's ESPP, adding 7,446 shares. The net effect on total beneficial ownership is explicitly stated as 474,862 shares. This filing reports execution details and ownership counts without additional context such as a change in long-term holdings, option exercises, or derivative activity. For investors, the document provides clear transactional mechanics but no new operational or financial information about the company.

Corporate Governance Expert

TL;DR: Disclosure follows Section 16 requirements; transactions are routine and properly reported by POA.

The report identifies the reporting person, relationship (Chief Financial Officer), transaction dates, quantities, prices, and the stated reason for the sale (tax withholding on vested RSUs). It also discloses ESPP acquisitions included in the post-transaction beneficial ownership total. The filing bears a signature executed by power of attorney, which is noted on the form. There are no indications of late reporting, unexplained transfers, or derivative transactions in this submission.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Halladay Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		S		7,046(1)	D	$2.808	474,862(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

2. Includes 7,446 shares recently acquired in Esperion's Employee Stock Purchase Plan.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.